The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy
Open accessAbstract
Following the discovery of the first effective antiviral compound (idoxuridine) in 1959, nucleoside analogues, especially acyclovir (ACV) for the treatment of herpesvirus infections, have dominated antiviral therapy for several decades. However, ACV and similar acyclic nucleosides suffer from low aqueous solubility and low bioavailability following oral administration. Derivatives of acyclic nucleosides, typically esters, were developed to overcome this problem and valaciclovir, the valine ester of ACV, was among the first of a new series of compounds that were readily metabolized upon oral administration to produce the antiviral nucleoside in vivo, thus increasing the bioavailility by several fold. Concurrently, famciclovir was developed as an oral formulation of penciclovir. These antiviral ‘prodrugs’ thus established a principle that has led to many successful drugs including both nucleoside and nucleotide analogues for the control of several virus infections, notably those caused by herpes‐, retro‐ and hepatitisviruses. This review will chart the origins and development of the most important of the antiviral prodrugs to date. British Journal of Pharmacology(2006)147, 1–11. doi:10.1038/sj.bjp.0706446
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341
Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
Corey, L., Wald, A., Patel, R., Sacks, S. L., Tyring, S. K., Warren, T., Douglas, J. M., Paavonen, J., Morrow, R. A., Beutner, K. R., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035144 · Cited by 720
Mertz, G. J. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440240109016 · Cited by 121 · cited 1×
“…famciclovir has been established to be effective against HSV-1-and -2 for both therapy and long-term suppression of recurrences (Sacks et al., 1996; Mertz et al., 1997) and is also claimed to be efficacious in treatment of herpes zoster (Degreef & Famciclovir Herpes Zoster Clinical Study Group,…”
Background
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Self-citationPrescribed drugs containing nitrogen heterocycles: an overview
Heravi, M. M., & Zadsirjan, V. (2020) · RSC Advances · doi:10.1039/d0ra09198g · Cited by 1,194
Tariq, S., Wani, S., Rasool, W., Shafi, K., Bhat, M. A., Prabhakar, A., Shalla, A. H., & Rather, M. A. (2019) · Microbial Pathogenesis · doi:10.1016/j.micpath.2019.103580 · Cited by 693
Seley-Radtke, K. L., & Yates, M. K. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.004 · Cited by 543
Cellular Uptake of Nanoparticles versus Small Molecules: A Matter of Size
Mosquera, J., García, I., & Liz-Marzán, L. M. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00292 · Cited by 487
Metadata
- Authors
- De Clercq, E., & Field, H. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2006-01
- Volume
- 147
- Issue
- 1
- Pages
- 1-11
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2033899181
- Cited by
- 336
- References
- 4
- FWCI
- 10.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy. https://app.cochat.ai/papers/10.1038/sj.bjp.0706446
- The paper
- De Clercq, E., & Field, H. J. (2006). Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0706446
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.